Short Interest in MDxHealth SA (NASDAQ:MDXH) Expands By 81.0%

MDxHealth SA (NASDAQ:MDXH) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 56,300 shares, an increase of 81.0% from the February 28th total of 31,100 shares. Based on an average trading volume of 104,100 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are sold short.

MDxHealth Price Performance

Shares of MDXH traded down $0.01 during midday trading on Friday, hitting $1.51. 42,930 shares of the company traded hands, compared to its average volume of 85,028. MDxHealth has a 52 week low of $1.35 and a 52 week high of $3.50. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The firm has a 50 day moving average of $1.75 and a 200-day moving average of $1.99. The stock has a market cap of $71.40 million, a price-to-earnings ratio of -0.99 and a beta of 1.37.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. On average, analysts forecast that MDxHealth will post -1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. boosted its holdings in shares of MDxHealth by 31.6% in the 4th quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company’s stock worth $2,331,000 after purchasing an additional 236,100 shares during the period. Oppenheimer & Co. Inc. increased its position in MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock valued at $47,000 after acquiring an additional 10,000 shares during the last quarter. Maven Securities LTD purchased a new stake in shares of MDxHealth in the third quarter valued at $208,000. Northern Trust Corp purchased a new position in shares of MDxHealth during the 4th quarter worth about $1,033,000. Finally, AWM Investment Company Inc. grew its holdings in MDxHealth by 11.1% during the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company’s stock valued at $11,189,000 after purchasing an additional 471,290 shares during the last quarter.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.